Small molecule glucagonR antagonist

Glucagon is a 29 amino acid peptide hormone liberated in the alpha cells of the islets of Langerhans. Glucagon has in general been viewed as the counter regulatory hormone to insulin in peripheral tissues, predominantly to the liver. An important contributor to the development of hyperglycemia in type 2 diabetes is inappropriately high glucose production from the liver. The primary physiological effect of glucagon is to stimulate hepatic glucose production by increasing both gluconeogenesis and glycogenolysis. 

NNC0025-0926 was developed as an oral bioavailable small molecule capable of antagonizing glucagon signaling and thereby shut down the contribution from glucagon to hyperglycemia in T2DM.